secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001558370-25-002595
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus swings to FY 2024 net income of $28.5M; UDENYCA divestiture on track
----------------------------------------------------------------------------

- FY 2024 net income $28.5M ($0.25 diluted EPS) vs net loss $237.9M in FY 2023; revenue $267M, +4%.
- UDENYCA net revenue $206M (+62% YoY); LOQTORZI Q4 revenue $7.5M, +29% QoQ.
- Non-GAAP net loss $86.3M ($0.75 loss per share) improved from $186.2M in FY 2023.
- UDENYCA divestiture up to $558.4M; shareholder vote March 11, expected close late Q1/early Q2 2025.
- Post-divestiture projected cash ~$250M, cash runway >2 years; headcount reduction ~30%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025002595/0001558370-25-002595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025002595/chrs-20250310x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer